UK markets closed

AxoGen, Inc. (AXGN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
6.10-0.10 (-1.61%)
As of 03:30PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close6.20
Open6.20
Bid6.08 x 100
Ask6.12 x 100
Day's range5.90 - 6.20
52-week range3.45 - 10.83
Volume106,713
Avg. volume328,083
Market cap266.598M
Beta (5Y monthly)1.06
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date27 Jan 2010
1y target estN/A
All
News
  • GlobeNewswire

    Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®

    ALACHUA, Fla. and TAMPA, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, is pleased to announce that it has initiated the rolling submission process with the U.S. Food and Drug Administration for a Biologics License Application (BLA) for licensure of Avance Nerve Graft® on May 15, 2024. “Today’s milestone represents a significant step in our regulatory transition of Avance

  • GlobeNewswire

    Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference

    ALACHUA, Fla. and TAMPA, Fla., May 14, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, chairman, chief executive officer, and president, will participate in a fireside chat at the Leerink Partners Healthcare Crossroads Conference in Austin, TX, on Wednesday, May 29, 2024, at 3:40 p.m. CT / 4:40 p.m. ET. Webcast events can be accessed live through the

  • GlobeNewswire

    Axogen, Inc Reports First Quarter 2024 Financial Results

    ALACHUA, Fla. and TAMPA, Fla., May 02, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2024. First Quarter Financial Results First quarter revenue was $41.4 million, a 12.9% increase compared to the first quarter of 2023.In the first quarter of 2024, our gross margin increased to 78.8%, up fro